Biomarkers Consortium – CSC Scientific Symposium

Each year, the CSC brings together experts from academia, pharmaceutical companies, biotechnology companies, not-for-profit organizations, the NIH and the FDA to participate in this symposium to review advances in the field of biomarker and regulatory science that are relevant to the development of new public-private partnerships for precompetitive biomarkers. The CSC Scientific Symposium thus serves as an opportunity each year to assess and recalibrate future directions in biomarker discovery and development. Topic areas covered include analytical validation and clinical utility of liquid biopsy, project opportunities around immuno-oncology biomarkers, cross-disease analysis of biomarker initiatives in the microbiome, and Minimal Residual Disease in blood-based cancers.


  • Discuss cutting edge science, including projects supported by the FNIH BC.
  • Inform the field of the latest developments in critical areas of biomarker science.
  • Guide CSC decision making and project planning.

For more information on how to partner with us, please contact

Results & Accomplishments

Demonstrating the diversity of the biomarker science discussed, the previous years' agendas showcased projects across the ecosystem of precision medicine and biomarker development, including MRD, liquid biopsy, novel imaging improvement, cell-free RNA and DNA research, and immuno-oncology. Cross-disease analysis of non-cancer biomarker initiatives also provided discussion to assess approaches for collaboration across the field of medicine.


2019 Symposium Agenda

2019 Symposium Executive Summary

2018 Symposium Agenda

2018 Symposium Executive Summary

2017 Symposium Agenda

2017 Symposium Overview

2016 Symposium Agenda

2016 Symposium Executive Summary

2015 Symposium Executive Summary

Previous Partners

Public-Sector Partners
National Cancer Institute
Society for Immunotherapy of Cancer (SITC)*
U.S. Food and Drug Administration (FDA)

Private-Sector Partners
AbbVie Inc.*
Adaptive Biotechnologies*
Amgen, Inc.*
AstraZeneca Pharmaceuticals, LP*
Bayer HealthCare Pharmaceuticals Inc.*
Bristol-Myers Squibb Company*
Genentech, a member of the Roche Group*
Janssen Oncology*
Pfizer, Inc.*
Takeda Oncology*

*Provides financial or in-kind support for this program.

FNIH Contacts

Stacey J. Adam, Ph.D., Director, Cancer,

Dana E. Connors, Senior Project Manager, Cancer,

Emily Morgan, Scientific Project Manager, Research Partnerships,